These results indicate that BRAF inhibition by dabrafenib, MEK inhibition by trametinib, and dual BRAF/MEK inhibition by dabrafenib+trametinib induce the SEMA6A/RhoA/YAP axis in BRAF-mut but not in BRAF-wt melanoma cells. This evidence concerns the gene SEMA6A and melanoma.